DK2252581T3 - Kappa-selektiv opioidreceptorantagonist - Google Patents

Kappa-selektiv opioidreceptorantagonist

Info

Publication number
DK2252581T3
DK2252581T3 DK09703808.7T DK09703808T DK2252581T3 DK 2252581 T3 DK2252581 T3 DK 2252581T3 DK 09703808 T DK09703808 T DK 09703808T DK 2252581 T3 DK2252581 T3 DK 2252581T3
Authority
DK
Denmark
Prior art keywords
cape
receptor antagonist
opioid receptor
selective opioid
selective
Prior art date
Application number
DK09703808.7T
Other languages
Danish (da)
English (en)
Inventor
Buezo Nuria Diaz
David Lee Mckinzie
Charles Howard Mitch
Concepcion Pedregal-Tercero
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK2252581T3 publication Critical patent/DK2252581T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
DK09703808.7T 2008-01-22 2009-01-13 Kappa-selektiv opioidreceptorantagonist DK2252581T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08380012 2008-01-22
US3912108P 2008-03-25 2008-03-25
PCT/US2009/030811 WO2009094260A1 (en) 2008-01-22 2009-01-13 Kappa selective opioid receptor antagonist

Publications (1)

Publication Number Publication Date
DK2252581T3 true DK2252581T3 (da) 2012-07-16

Family

ID=40876972

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09703808.7T DK2252581T3 (da) 2008-01-22 2009-01-13 Kappa-selektiv opioidreceptorantagonist

Country Status (32)

Country Link
US (2) US7709522B2 (enExample)
EP (1) EP2252581B1 (enExample)
JP (1) JP5345637B2 (enExample)
KR (1) KR101172170B1 (enExample)
CN (1) CN101925576B (enExample)
AR (1) AR070158A1 (enExample)
AU (1) AU2009206653B2 (enExample)
BR (1) BRPI0907382B8 (enExample)
CA (1) CA2713025C (enExample)
CO (1) CO6290644A2 (enExample)
CY (1) CY1113071T1 (enExample)
DK (1) DK2252581T3 (enExample)
DO (1) DOP2010000222A (enExample)
EA (1) EA017484B1 (enExample)
EC (1) ECSP10010365A (enExample)
ES (1) ES2388708T3 (enExample)
HR (1) HRP20120558T1 (enExample)
IL (1) IL206038A (enExample)
JO (1) JO2797B1 (enExample)
MA (1) MA32751B1 (enExample)
MX (1) MX2010007849A (enExample)
MY (1) MY163014A (enExample)
NZ (1) NZ586225A (enExample)
PE (1) PE20091317A1 (enExample)
PL (1) PL2252581T3 (enExample)
PT (1) PT2252581E (enExample)
SI (1) SI2252581T1 (enExample)
TN (1) TN2010000306A1 (enExample)
TW (1) TWI422369B (enExample)
UA (1) UA100715C2 (enExample)
WO (1) WO2009094260A1 (enExample)
ZA (1) ZA201003908B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009093747A1 (en) * 2008-01-22 2009-07-30 Takeda Pharmaceutical Company Limited Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them
CA2713025C (en) * 2008-01-22 2012-12-04 Eli Lilly And Company Kappa selective opioid receptor antagonist
EP2757881A4 (en) 2011-09-15 2014-11-12 Univ Kansas KAPPA OPIATE RECEPTOR EFFECTORS AND USES THEREOF
WO2013042054A1 (en) 2011-09-19 2013-03-28 Carmel - Haifa University Economic Corporation Ltd. Buprenorphine for the treatment of acute suicidality
CA2858752C (en) 2011-12-09 2019-12-31 Research Triangle Institute 1-substituted 4-arylpiperazines as kappa opioid receptor antagonists
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US9283196B1 (en) 2013-01-30 2016-03-15 MediSynergics, LLC Cycloalkyl-diamines for CNS disorders
NZ631018A (en) * 2013-05-24 2017-12-22 Alkermes Pharma Ireland Ltd Morphan and morphinan analogues, and methods of use
US10316021B2 (en) * 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
MX388721B (es) 2017-03-17 2025-03-20 Scripps Research Inst Antagonistas del receptor opioide kappa y productos y metodos relacionados al mismo.
JP6480616B1 (ja) 2018-02-08 2019-03-13 有限会社 ディオン光学技研 照準スコープ
US11266627B1 (en) 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CN114195693A (zh) * 2020-09-17 2022-03-18 广东东阳光药业有限公司 一种酰胺化合物的晶型及其制备方法
CN114591211B (zh) * 2020-12-04 2025-10-21 广东东阳光药业股份有限公司 一种酰胺化合物的共晶及其制备方法
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
KR20240004857A (ko) 2021-05-04 2024-01-11 얀센 파마슈티칼즈, 인코포레이티드 우울증 치료를 위한 조성물 및 방법
AU2023205471A1 (en) * 2022-01-10 2024-08-29 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
IL314176A (en) * 2022-01-10 2024-09-01 Janssen Pharmaceuticals Inc Compositions and methods for treating depression
CN119156211A (zh) 2022-03-07 2024-12-17 杨森制药公司 用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰
KR20240152410A (ko) * 2022-03-07 2024-10-21 얀센 파마슈티칼즈, 인코포레이티드 아티카프란트를 포함하는 조성물
JP2025508071A (ja) * 2022-03-07 2025-03-21 ヤンセン ファーマシューティカルズ,インコーポレーテッド 純粋な形態の結晶質アチカプラント
JP7176142B1 (ja) 2022-03-09 2022-11-21 直迪 清瀬 各アルコール飲用者において飲用し得るアルコール飲料の種類に対応する飲用量の上限値に関する情報を提供するシステム

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457208A (en) * 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
CN1164590C (zh) * 1999-05-12 2004-09-01 弗·哈夫曼-拉罗切有限公司 咪唑二氮杂�衍生物
JP2004510789A (ja) * 2000-10-05 2004-04-08 モーラー,ハンス 選択的抗不安治療薬
EP1353665A4 (en) * 2000-12-21 2004-05-06 Mclean Hospital Corp Treatment of depression
US6974824B2 (en) 2001-01-08 2005-12-13 Research Triangle Institute Kappa opioid receptor ligands
IL163958A0 (en) * 2002-03-28 2005-12-18 Wisys Technology Foundation Anxiolytic agents with reduced sedative and ataxideffects
UA80437C2 (en) * 2002-09-19 2007-09-25 Lilly Co Eli Diaryl ethers as opioid receptor antagonist
AU2004220112A1 (en) * 2003-03-07 2004-09-23 Eli Lilly And Company 6-substituted nicotinamide derivatives as opioid receptor antagonists
MXPA05009367A (es) * 2003-03-07 2005-11-04 Lilly Co Eli Antagonistas del receptor opioide.
BRPI0417156A (pt) * 2003-12-12 2007-03-06 Lilly Co Eli composto, composição farmacêutica, e, métodos para bloquear receptor mu, capa, delta ou combinação (heterodìmero) dos mesmos em mamìferos, para tratar e/ou prevenir doenças relacionadas com obesidade e obesidade, para suprimir apetite em um paciente, para efetuar perda de peso em um paciente obeso
WO2005066164A1 (en) * 2003-12-22 2005-07-21 Eli Lilly And Company Opioid receptor antagonists
AU2005222640A1 (en) * 2004-03-12 2005-09-29 The Mclean Hospital Corporation Salvinorin derivatives and uses thereof
ES2308471T3 (es) * 2004-03-12 2008-12-01 Eli Lilly And Company Antagonistas de receptores de opioides.
US7381750B2 (en) * 2004-03-12 2008-06-03 Eli Lilly And Company Amino-phenoxymethyl-benzamide opioid receptor antagonists
ATE545413T1 (de) * 2004-03-15 2012-03-15 Lilly Co Eli Antagonisten des opioidrezeptors
JP2007529523A (ja) * 2004-03-15 2007-10-25 イーライ リリー アンド カンパニー 肥満症を治療するためのオピオイド受容体拮抗物質としての4−(5−アミノメチル)−インドール−1−イルメチル)−ベンズアミド誘導体および関連化合物
WO2007067714A2 (en) * 2005-12-08 2007-06-14 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
DK2001456T3 (da) 2006-04-04 2010-04-12 Emodys Gmbh Anvendelse af kappa-opiodreceptorantagonistholde sammensætninger til behandling af dissociative forstyrrelser
JP2010500372A (ja) 2006-08-09 2010-01-07 スミスクライン ビーチャム コーポレーション オピオイド受容体に対するアンタゴニストまたはインバースアゴニストとしての新規化合物
CN102516115B (zh) 2006-08-09 2016-05-11 史密丝克莱恩比彻姆公司 作为阿片样物质受体的拮抗剂或反向激动剂的新型化合物
CN101511808A (zh) 2006-09-08 2009-08-19 辉瑞产品公司 二芳基醚衍生物及其用途
CA2713025C (en) * 2008-01-22 2012-12-04 Eli Lilly And Company Kappa selective opioid receptor antagonist

Also Published As

Publication number Publication date
KR20100095639A (ko) 2010-08-31
US20090186873A1 (en) 2009-07-23
IL206038A0 (en) 2010-11-30
HRP20120558T1 (hr) 2012-10-31
IL206038A (en) 2013-11-28
KR101172170B1 (ko) 2012-08-07
ES2388708T3 (es) 2012-10-17
BRPI0907382B1 (pt) 2020-03-10
MY163014A (en) 2017-07-31
BRPI0907382B8 (pt) 2021-05-25
AU2009206653A1 (en) 2009-07-30
ECSP10010365A (es) 2010-08-31
US8173695B2 (en) 2012-05-08
CA2713025A1 (en) 2009-07-30
EA201070877A1 (ru) 2010-12-30
EP2252581A1 (en) 2010-11-24
PT2252581E (pt) 2012-08-31
TN2010000306A1 (en) 2011-11-11
PL2252581T3 (pl) 2012-10-31
EA017484B1 (ru) 2012-12-28
PE20091317A1 (es) 2009-09-03
MA32751B1 (fr) 2011-11-01
TW200936129A (en) 2009-09-01
JO2797B1 (en) 2014-03-15
US7709522B2 (en) 2010-05-04
AR070158A1 (es) 2010-03-17
SI2252581T1 (sl) 2012-09-28
BRPI0907382A2 (pt) 2015-07-21
MX2010007849A (es) 2010-08-09
CA2713025C (en) 2012-12-04
JP2011524850A (ja) 2011-09-08
CO6290644A2 (es) 2011-06-20
ZA201003908B (en) 2011-11-30
JP5345637B2 (ja) 2013-11-20
NZ586225A (en) 2012-05-25
CN101925576A (zh) 2010-12-22
TWI422369B (zh) 2014-01-11
HK1146822A1 (en) 2011-07-15
CY1113071T1 (el) 2016-04-13
AU2009206653B2 (en) 2013-07-18
UA100715C2 (ru) 2013-01-25
US20100197669A1 (en) 2010-08-05
CN101925576B (zh) 2013-02-06
WO2009094260A1 (en) 2009-07-30
EP2252581B1 (en) 2012-06-20
DOP2010000222A (es) 2015-11-15

Similar Documents

Publication Publication Date Title
DK2252581T3 (da) Kappa-selektiv opioidreceptorantagonist
HUS2200033I1 (hu) CGRP receptor antagonisták
HUS2200025I1 (hu) C5AR antagonisták
LTC2379069I2 (lt) S1p receptoriaus agonisto dozavimas
EP2350060A4 (en) Melanocortin receptor AGONISTS
BRPI0910118A2 (pt) antagonistas de receptores do glucagon
DK2821407T3 (da) Piperidinoncarboxamidazaindan-cgrp receptorantagonister
EP2150115A4 (en) CYCLOPROPYLPYRROLIDINOREXIN Receptor Antagonists
BRPI0923512A2 (pt) antagonistas de receptores de ácido lisofosfatídico
BRPI0913930A2 (pt) antagonistas de receptores de prostaglandinas d2
BRPI0919539A2 (pt) antagonistas de receptor de opioide periférico e empregos dos mesmos
BRPI0918760A2 (pt) compostos morfinanos
DK2501703T3 (da) Spiropiperidinforbindelser som orl-1-receptorantagonister
BRPI1016189A2 (pt) compostos de 4-azetidinil-1-fenil-ciclohexano antagonistas de ccr2
HRP20170246T1 (hr) Režim doziranja za selektivni agonist s1p1-receptora
BRPI0810926A2 (pt) Antagonista de crig
ATE509022T1 (de) Nikotin-acetylcholin-rezeptorsubtyp-selektive diazabicycloalkanamide
DK2081951T3 (da) Progesteron-receptorantagonister
SMT201400113B (it) Nalmefene cloridrato diidrato
DK2009992T3 (da) Il-8 receptor-antagonister
IL208355A0 (en) Heterocyclic copmpounds as adenosine receptor antagonist
DK2799428T3 (da) Glucagon-antagonister
HRP20160950T1 (hr) Polimorfi antagonista mglur5 receptora
BR112012003976A2 (pt) antagonistas de receptor glyt1 carbocíclico
BRPI0821611A2 (pt) Derivado de 3-carboxipropil-aminotetralina e compostos relacionados como antagonistas de receptor opióide mu